Monte Rosa Therapeutics (GLUE) Other Non-Current Assets (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Other Non-Current Assets of $4.9 million for Q1 2026, up 1.37% year-over-year from $4.9 million in Q1 2025, and up 3242.57% quarter-over-quarter from $148000.0 in Q4 2025.
Monte Rosa Therapeutics (GLUE) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $4.9 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 1.37% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (up 1.37% YoY), while the FY2025 annual figure was $148000.0, down 96.96% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $4.9 million, up from $148000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.3 million in Q1 2022, with the low at $148000.0 in Q4 2025.
- The 5-year median for Other Non-Current Assets is $4.9 million (2024), against an average of $4.1 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets jumped 1281.53% in 2024, then plunged 96.96% in 2025.
- Monte Rosa Therapeutics' Other Non-Current Assets stood at $4.3 million in 2022, then tumbled by 91.85% to $352000.0 in 2023, then surged by 1281.53% to $4.9 million in 2024, then slumped by 96.96% to $148000.0 in 2025, then surged by 3242.57% to $4.9 million in 2026.
- Business Quant data shows GLUE's Other Non-Current Assets at $4.9 million in Q1 2026, $148000.0 in Q4 2025, and $411000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 4.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.94 Mn |
| Mar 31, 2026 | 4.95 Mn |
| Dec 31, 2025 | 148,000.00 |
| Sep 30, 2025 | 411,000.00 |
| Jun 30, 2025 | 4.95 Mn |
| Mar 31, 2025 | 4.88 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 4.91 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 4.86 Mn |
| Dec 31, 2023 | 352,000.00 |
| Sep 30, 2023 | 4.52 Mn |
| Jun 30, 2023 | 4.53 Mn |
| Mar 31, 2023 | 5.28 Mn |
| Dec 31, 2022 | 4.32 Mn |
| Sep 30, 2022 | 5.26 Mn |
| Jun 30, 2022 | 5.32 Mn |
| Mar 31, 2022 | 5.33 Mn |
| Dec 31, 2021 | 5.34 Mn |
| Sep 30, 2021 | 1.73 Mn |